4D Molecular Therapeutics, Inc.
NASDAQ:FDMTBiotechnology
+$0.16 today
- Market cap
- $577.85M
- Beta
- 2.76
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$2.36
Volume 0.68M
Average 0.77M
FDMT Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
4D Molecular Therapeutics, Inc.NASDAQ: FDMT
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses declines year over year
Q1 FY2026 other income / expenses of $4.86M fell 14.0% year over year, ahead of the -30.6% change in trailing-twelve-month other income / expenses. Sequentially, it rose 3.8% from the prior quarter. Over 3 fiscal years it compounded at +97.1% a year.
Context
- Other income / expenses amounted to 22.8% of revenue in FY2025, down 72877.2 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -14.0% holds above the trailing-twelve-month pace of -30.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 19.44M USD
- Year-over-year change
- -27.9%
- 4-year CAGR
- +490.4%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.44M | -27.9% |
| FY2024 | 2024-12-31 | 26.97M | +124.2% |
| FY2023 | 2023-12-31 | 12.03M | +374.0% |
| FY2022 | 2022-12-31 | 2.54M | +15762.5% |
| FY2021 | 2021-12-31 | 16K | — |
Other Income / Expenses vs competitors
How FDMT compares with its peers on the latest reported figures
- FDMT's LTM Mar 2026 other income / expenses of $18.65M is the 2nd highest of the 8 companies compared; the peer median is -$5.42M.
- Its year-over-year change of -30.6% is the 5th highest of 8, against a peer median of +44.4%.
- Other income / expenses amounts to 21.1% of revenue for FDMT, versus a peer median of 65.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $158.99M | +525.4% | +142.9% | 1093.5% | |
| LTM Mar 2026 | $18.65M | -30.6% | +97.1% | 21.1% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $10.28M | +47.5% | +96.1% | — |
| LTM Mar 2026 | $4.68M | +44.4% | -38.0% | — | |
| LTM Mar 2026 | -$5.42M | -1137.2% | — | 121.4% | |
| LTM Mar 2026 | -$11.92M | +74.0% | — | 65.9% | |
| LTM Mar 2026 | -$15.34M | -85.0% | — | 19.2% | |
| LTM Mar 2026 | -$33.33M | -9907.5% | — | 37.9% | |
| Peer median (excluding FDMT) | -$5.42M | +44.4% | +96.1% | 65.9% | |
Competitors are the stored peer set for FDMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.04M | 3.13M | 20.72M | 37K | 85.21M |
| Cost of Revenue | 61.36M | 80.25M | 97.1M | 141.3M | 7.63M |
| Gross Profit | (43.32M) | (77.12M) | (76.37M) | (141.26M) | 77.58M |
| Gross Margin | -240.2% | -2464.8% | -368.5% | -381789.2% | 91.1% |
| Research & Development | 61.36M | 80.25M | 97.1M | 141.3M | 195.7M |
| Selling, General & Admin | 28.01M | 32.91M | 36.49M | 46.58M | 49.06M |
| Operating Expenses | 28.01M | 32.91M | 36.49M | 46.58M | 237.13M |
| Depreciation & Amortization | 1.52M | 2.4M | 4.2M | 6.71M | 7.63M |
| EBITDA | (69.79M) | (105.09M) | (96.63M) | (154.16M) | (132.48M) |
| EBITDA Margin | -386.9% | -3358.6% | -466.3% | -416656.8% | -155.5% |
| Operating Income | (71.33M) | (110.03M) | (112.87M) | (187.84M) | (159.55M) |
| Operating Margin | -395.5% | -3516.5% | -544.6% | -507678.4% | -187.2% |
| Interest Income | 137K | 2.57M | 12.21M | 27.05M | 19.48M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 16K | 2.54M | 12.03M | 26.97M | 19.44M |
| Income Before Tax | (71.32M) | (107.49M) | (100.84M) | (160.87M) | (140.11M) |
| Pre-Tax Margin | -395.4% | -3435.4% | -486.6% | -434778.4% | -164.4% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (71.32M) | (107.49M) | (100.84M) | (160.87M) | (140.11M) |
| Net Margin | -395.4% | -3435.4% | -486.6% | -434778.4% | -164.4% |
| EPS (Basic) | (2.46) | (3.12) | (2.58) | (2.98) | (2.42) |
| EPS (Diluted) | (2.46) | (3.12) | (2.58) | (2.98) | (2.42) |
| Weighted Avg Shares | 27.73M | 32.35M | 39.13M | 53.94M | 57.93M |
| Weighted Avg Shares (Diluted) | 27.73M | 32.35M | 39.13M | 53.94M | 57.93M |
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
Intrinsic Alpha fair value
Locked
Current Price
$10.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.